Abstract
The age of menopause is associated with fertility and disease risk, and its genetic control is of great interest. We used whole-exome sequences from 119,992 women in the UK Biobank to test for associations between rare damaging variants and age at natural menopause. Rare damaging variants in three genes significantly associated with menopause: CHEK2 (p = 6.2 × 10−51) and DCLRE1A (p = 1.2 × 10−12) with later menopause and TOP3A (p = 8.8 × 10−8) with earlier menopause. Two additional genes were suggestive: RAD54L (p = 2.3 × 10−6) with later menopause and HROB (p = 2.7 × 10−6) with earlier menopause. In a follow-up analysis of repeated questionnaires in women who were initially pre-menopausal, CHEK2, TOP3A, and RAD54L genotype associated with subsequent menopause. Consistent with previous GWAS, all five genes are involved in the DNA-damage repair pathway. Phenome-wide scans across 363,977 men and women revealed that in addition to known associations with cancers and blood cell counts, rare variants in CHEK2 also associated with increased risk of uterine fibroids, polycystic ovary syndrome, and prostate hypertrophy; these associations are not shared with higher-penetrance breast cancer genes. Causal mediation analysis suggests that approximately 8% of the breast cancer risk conferred by CHEK2 pathogenic variants after menopause is mediated through delayed menopause.
Competing Interest Statement
All authors are employees of Alnylam Pharmaceuticals.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was received to use these data from the UK Biobank under application number 26041. The UK Biobank resource is an approved Research Tissue Bank and is registered with the Human Tissue Authority, which means that researchers who wish to use it do not need to seek separate ethics approval (unless re-contact with participants is required). Ethics oversight for the UK Biobank is provided by an Ethics and Governance Council which obtained written informed consent from all participants for use of the data in health-related research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study were obtained from the UKBB through application 26041. All phenotypic data and array genotypes are accessible through application to UK Biobank. Currently, exome sequencing data for ∼200,000 participants is available; the remainder of the exome data is scheduled for public release in 2021.
